Will Tax Rules Derail AbbVie-Shire Deal?

The transcript discusses the market's reaction to a potential deal involving Shire and AbbVie, highlighting the board's recommendation against the deal due to potential changes in US law affecting tax benefits. It explores Shire's ability to remain independent and AbbVie's strategic challenges, including a significant product going off-patent. The discussion also touches on speculation about future moves by other companies like Pfizer.

What factors contributed to the market's decision regarding the Shire deal?

What was the board's recommendation to shareholders regarding the deal?

How did changes in US law impact the Shire and AbbVie deal?

What was the market reaction in terms of market cap related to Shire?

What potential future strategies might Shire consider following the deal discussions?